The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | Using patient-derived organoids to investigate bispecific T-cell engager immunotherapy in FL
Joseph Schroers-Martin, MD, Stanford University School of Medicine, Palo Alto, CA, discusses the use of patient-derived lymphoma organoid (PDLO) systems for investigating bispecific T-cell engager immunotherapies in follicular lymphoma (FL). Dr Schroers-Martin describes the robust PDLO models which were generated to replicate the FL tumor microenvironment (TME), allowing for testing of CD19xCD3 and CD20xCD3 bispecific antibodies, and expresses his hope for the use of PDLOs in personalized medicine. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
